TABLE 2.
Maternal urinary CTX in EP and LP and conditional change in CTX from EP to LP, in all mothers in the MAVIDOS (Maternal Vitamin D Osteoporosis Study) trial CTX substudy with a measure of EP or LP CTX, and in the placebo group and 1000 IU cholecalciferol–supplemented groups separately; and in all mothers with a measure of both EP and LP CTX, and in the placebo group and 1000 IU cholecalciferol–supplemented groups separately1
| All | Placebo | 1000 IU cholecalciferol/d | |||||
|---|---|---|---|---|---|---|---|
| n | Value | n | Value | n | Value | P value2 | |
| Participants with EP or LP CTX measures | |||||||
| EP CTX, µg/mmol creatinine | 493 | 219.4 [154.7–306.4] | 242 | 223.8 [155.0–308.6] | 251 | 217.5 [154.5–305.2] | N/A |
| LP CTX, µg/mmol creatinine | 498 | 437.4 [292.3–633.0] | 252 | 445.3 [317.6–657.3] | 246 | 420.0 [252.2–608.5] | 0.06 |
| Participants with both EP and LP CTX measures | |||||||
| EP CTX, µg/mmol creatinine | 372 | 223.0 [159.5–316.4] | 188 | 223.6 [153.6–311.8] | 184 | 222.3 [169.2–319.8] | N/A |
| LP CTX, µg/mmol creatinine | 372 | 429.6 [291.0–660.6] | 188 | 449.7 [327.3–687.2] | 184 | 419.3 [238.9–629.9] | 0.03 |
| Δ CTX, z score | 188 | 0.16 ± 0.92 | 184 | −0.16 ± 1.06 | <0.01 | ||
| Δ CTX (absolute) | 188 | 258.1 ± 322.1 | 184 | 214.5 ± 316.7 | 0.19 | ||
| Vitamin D–sufficient women, baseline 25(OH)D ≥ 50 nmol/L | |||||||
| EP CTX, µg/mmol creatinine | 168 | 232.8 [167.0–317.6] | 81 | 239.3 [175.2–326.9] | 87 | 225.3 [163.4–303.4] | N/A |
| LP CTX, µg/mmol creatinine | 161 | 409.1 [286.3–573.2] | 75 | 398.7 [300.0–573.2] | 86 | 414.4 [265.8–604.8] | 0.96 |
| Δ CTX, z score | 61 | −0.14 ± 0.92 | 61 | −0.17 ± 1.11 | 0.85 | ||
| Vitamin D–insufficient women, baseline 25(OH)D < 50 nmol/L | |||||||
| EP CTX, µg/mmol creatinine | 320 | 215.8 [142.7–303.2] | 159 | 216.0 [148.0–299.6] | 161 | 215.7 [139.7–307.5] | N/A |
| LP CTX, µg/mmol creatinine | 335 | 444.5 [293.2–660.4] | 176 | 459.7 [333.8–675.9] | 159 | 422.1 [249.5–633.0] | <0.01 |
| Δ CTX, z score | 126 | 0.28 ± 0.89 | 123 | −0.15 ± 1.04 | <0.01 | ||
1Values are median [IQR] or mean ± SD unless otherwise indicated. Change in CTX was calculated with a regression model with 34-wk CTX as the dependent variable and adjusting for 14-wk CTX; absolute change in CTX is also shown. Participants were further stratified according to vitamin D sufficiency (≥50 nmol/L or insufficiency < 50 nmol/L) in EP. EP = 14 weeks of gestation; LP = 34 weeks of gestation; ΔCTX = conditional change in CTX (LP CTX adjusted for EP CTX), in SD. N/A, not applicable; CTX, C-terminal telopeptide of type I collagen; EP, early pregnancy; LP, late pregnancy; 25(OH)D, 25-hydroxyvitamin D.
2 P values represent outcomes of tests for differences between the placebo group and vitamin D–supplemented group [Rank Sum tests for LP CTX, t tests for Δ CTX (z score)].